Movement Alert｜AKESO Rises 3.03% in Regular Trading, Ivonescimab Biliary Tract Cancer Phase 3 Meets Primary OS Endpoint Amid Interim Results Release

Market Focus08-27

On August 27, AKESO rose 3.03% in regular trading, trading at 97.65 HKD/share, with turnover of HKD 175 million.

On the news front, the company announced on August 26 that its PD-1/VEGF bispecific antibody ivonescimab plus chemotherapy achieved the primary endpoint of overall survival in the Phase 3 HARMONi-GI1 trial for first-line treatment of advanced biliary tract cancer, demonstrating statistically significant and clinically meaningful superiority over durvalumab plus chemotherapy. Key secondary endpoints of progression-free survival and objective response rate were also met. The study enrolled 682 patients and represents the first Phase 3 trial in biliary tract cancer to show significant OS improvement over the global standard of care, marking ivonescimab's expansion from lung cancer into gastrointestinal tumors.

Additionally, the company's board is scheduled to review and release interim results on August 27, providing further near-term catalyst. Ivonescimab's third indication was approved on August 12 for first-line squamous NSCLC, with commercial ramp trajectory drawing market attention.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1187410603?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-27 09:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1187410603","market":"us","top_or_hot":-1,"title":"Movement Alert｜AKESO Rises 3.03% in Regular Trading, Ivonescimab Biliary Tract Cancer Phase 3 Meets Primary OS Endpoint Amid Interim Results Release","media":"Market Focus","content":"<p><p>On August 27, AKESO rose 3.03% in regular trading, trading at 97.65 HKD/share, with turnover of HKD 175 million.</p><p>On the news front, the company announced on August 26 that its PD-1/VEGF bispecific antibody ivonescimab plus chemotherapy achieved the primary endpoint of overall survival in the Phase 3 HARMONi-GI1 trial for first-line treatment of advanced biliary tract cancer, demonstrating statistically significant and clinically meaningful superiority over durvalumab plus chemotherapy. Key secondary endpoints of progression-free survival and objective response rate were also met. The study enrolled 682 patients and represents the first Phase 3 trial in biliary tract cancer to show significant OS improvement over the global standard of care, marking ivonescimab's expansion from lung cancer into gastrointestinal tumors.</p><p>Additionally, the company's board is scheduled to review and release interim results on August 27, providing further near-term catalyst. Ivonescimab's third indication was approved on August 12 for first-line squamous NSCLC, with commercial ramp trajectory drawing market attention.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜AKESO Rises 3.03% in Regular Trading, Ivonescimab Biliary Tract Cancer Phase 3 Meets Primary OS Endpoint Amid Interim Results Release</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜AKESO Rises 3.03% in Regular Trading, Ivonescimab Biliary Tract Cancer Phase 3 Meets Primary OS Endpoint Amid Interim Results Release\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-27 09:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 27, AKESO rose 3.03% in regular trading, trading at 97.65 HKD/share, with turnover of HKD 175 million.</p><p>On the news front, the company announced on August 26 that its PD-1/VEGF bispecific antibody ivonescimab plus chemotherapy achieved the primary endpoint of overall survival in the Phase 3 HARMONi-GI1 trial for first-line treatment of advanced biliary tract cancer, demonstrating statistically significant and clinically meaningful superiority over durvalumab plus chemotherapy. Key secondary endpoints of progression-free survival and objective response rate were also met. The study enrolled 682 patients and represents the first Phase 3 trial in biliary tract cancer to show significant OS improvement over the global standard of care, marking ivonescimab's expansion from lung cancer into gastrointestinal tumors.</p><p>Additionally, the company's board is scheduled to review and release interim results on August 27, providing further near-term catalyst. Ivonescimab's third indication was approved on August 12 for first-line squamous NSCLC, with commercial ramp trajectory drawing market attention.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09926","symbol_name":"康方生物","start_time":0,"source_url":"","article_id":"1187410603","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1187410603","pubTimestamp":1787795021,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 27, AKESO rose 3.03% in regular trading, trading at 97.65 HKD/share, with turnover of HKD 175 million.On the news front, the company announced on August 26 that its PD-1/VEGF bispecific...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09926":"康方生物"},"translate_title":"走势警报|AKESO常规交易上涨3.03%，Ivonescimab胆管癌3期达到主要OS终点，中期业绩发布","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09926":1},"content_text":"On August 27, AKESO rose 3.03% in regular trading, trading at 97.65 HKD/share, with turnover of HKD 175 million.On the news front, the company announced on August 26 that its PD-1/VEGF bispecific antibody ivonescimab plus chemotherapy achieved the primary endpoint of overall survival in the Phase 3 HARMONi-GI1 trial for first-line treatment of advanced biliary tract cancer, demonstrating statistically significant and clinically meaningful superiority over durvalumab plus chemotherapy. Key secondary endpoints of progression-free survival and objective response rate were also met. The study enrolled 682 patients and represents the first Phase 3 trial in biliary tract cancer to show significant OS improvement over the global standard of care, marking ivonescimab's expansion from lung cancer into gastrointestinal tumors.Additionally, the company's board is scheduled to review and release interim results on August 27, providing further near-term catalyst. Ivonescimab's third indication was approved on August 12 for first-line squamous NSCLC, with commercial ramp trajectory drawing market attention.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.48.0","shortVersion":"4.48.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1187410603","isCrawlerRequest":true}